ClinicalTrials.Veeva

Menu

Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.

Stanford University logo

Stanford University

Status

Completed

Conditions

Diabetic Nephropathy

Treatments

Drug: Addition of furosemide 20 mg oral bid to baseline regimen

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00240019
R01-063011
R01DK063011 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The angiotensin converting enzyme inhibitor drugs are now standard therapy for patients with diabetic nephropathy. The hypothesis of this study is that adding a diuretic agent (furosemide) will decrease the urine protein, which is a sign of disease, more than an angiotensin converting enzyme inhibitor alone.

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

proteinuria greater than 1 gram/day serum creatinine < 2.6 for men, < 2.0 for women

Exclusion criteria

blood pressure which cannot be controlled without a diuretic renal diseases other than diabetic nephropathy other disease which would alter renal function during 6 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems